Sequoia Financial Advisors LLC Sells 2,818 Shares of Sanofi (NASDAQ:SNY)

Sequoia Financial Advisors LLC reduced its stake in shares of Sanofi (NASDAQ:SNY) by 13.4% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 18,229 shares of the company’s stock after selling 2,818 shares during the period. Sequoia Financial Advisors LLC’s holdings in Sanofi were worth $907,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Rise Advisors LLC lifted its stake in Sanofi by 98.4% in the fourth quarter. Rise Advisors LLC now owns 506 shares of the company’s stock worth $25,000 after purchasing an additional 251 shares during the last quarter. SRS Capital Advisors Inc. lifted its stake in Sanofi by 289.1% in the first quarter. SRS Capital Advisors Inc. now owns 463 shares of the company’s stock worth $25,000 after purchasing an additional 344 shares during the last quarter. Householder Group Estate & Retirement Specialist LLC bought a new stake in Sanofi in the third quarter worth $26,000. Fairfield Bush & CO. bought a new stake in Sanofi in the first quarter worth $26,000. Finally, Indiana Trust & Investment Management CO bought a new stake in Sanofi in the third quarter worth $27,000. 10.04% of the stock is owned by institutional investors.

Sanofi Price Performance

Shares of NASDAQ SNY opened at $45.93 on Monday. Sanofi has a 1 year low of $42.63 and a 1 year high of $57.82. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.87. The company’s 50-day moving average is $47.60 and its 200 day moving average is $48.81. The stock has a market capitalization of $116.18 billion, a P/E ratio of 19.46, a P/E/G ratio of 1.72 and a beta of 0.61.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Thursday, February 1st. The company reported $0.89 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.94 by ($0.05). Sanofi had a net margin of 12.56% and a return on equity of 27.47%. The company had revenue of $11.76 billion for the quarter, compared to analysts’ expectations of $13.02 billion. On average, sell-side analysts expect that Sanofi will post 4.16 earnings per share for the current year.

Sanofi Increases Dividend

The business also recently declared an annual dividend, which will be paid on Thursday, June 6th. Investors of record on Friday, May 10th will be given a dividend of $1.478 per share. The ex-dividend date of this dividend is Thursday, May 9th. This represents a dividend yield of 2.98%. This is a boost from Sanofi’s previous annual dividend of $1.38. Sanofi’s payout ratio is currently 58.47%.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on SNY shares. StockNews.com cut shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 27th. TheStreet cut shares of Sanofi from a “b” rating to a “c” rating in a research report on Friday, February 9th. Finally, Morgan Stanley started coverage on shares of Sanofi in a research report on Tuesday, January 23rd. They issued an “equal weight” rating and a $55.00 price objective on the stock. One research analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $55.00.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.